Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

8.380 +0.100 (+1.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level
CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year. 
Via Stocktwits
Topics Artificial Intelligence Earnings
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth
BioCryst Pharmaceuticals (BCRX) beats Q2 2025 estimates with strong revenue and profit growth, driven by ORLADEYO sales. Shares rise ~5% pre-market. 
Via Chartmill
BioCryst (BCRX) Q2 Revenue Jumps 50%
Via The Motley Fool
Earnings Scheduled For August 4, 2025
 
Via Benzinga
Earnings Outlook For BioCryst Pharma
 
Via Benzinga
BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering
BioCryst sells European Orladeyo rights to Neopharmed for up to $264 million, plans to eliminate term debt and boost long-term cash position. 
Via Benzinga
Earnings Scheduled For May 5, 2025
 
Via Benzinga
BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish
As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up... 
Via Stocktwits
BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria
BIOCRYST PHARMACEUTICALS (NASDAQ:BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors. 
Via Chartmill
BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria
BIOCRYST PHARMACEUTICALS (BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors. 
Via Chartmill
BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish
BioCryst Pharmaceuticals raised its 2025 revenue and expense forecasts, projecting net income and positive cash flow for the year. 
Via Stocktwits
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow. 
Via Benzinga
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
 
Via Benzinga
These stocks are gapping in today's session
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased
BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
Via The Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings
BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025. 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Earnings Scheduled For February 24, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
7 Small-Cap Stocks to Buy for Large-Scale Gains
Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling. 
Via InvestorPlace
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
 
Via Benzinga
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally. 
Via The Motley Fool
BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic... 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.